Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) is -67.49% lower on its value in year-to-date trading and has touched a low of $1.32 and a high of $8.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IRWD stock was last observed hovering at around $1.41 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $1.44, the stock is -2.57% and -25.73% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.52 million and changing 2.13% at the moment leaves the stock -64.43% off its SMA200. IRWD registered -83.28% loss for a year compared to 6-month loss of -65.05%. The firm has a 50-day simple moving average (SMA 50) of $1.9392 and a 200-day simple moving average (SMA200) of $4.0489.
The stock witnessed a -3.36% gain in the last 1 month and extending the period to 3 months gives it a -67.12%, and is -1.37% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.43% over the week and 8.19% over the month.
Ironwood Pharmaceuticals Inc (IRWD) has around 253 employees, a market worth around $233.00M and $351.41M in sales. Current P/E ratio is 133.33 and Fwd P/E is 6.65. Profit margin for the company is 0.52%. Distance from 52-week low is 9.09% and -83.18% from its 52-week high. The company has generated returns on investments over the last 12 months (0.61%).
The EPS is expected to grow by 325.00% this year
303.0 institutions hold shares in Ironwood Pharmaceuticals Inc (IRWD), with institutional investors hold 104.55% of the company’s shares. The shares outstanding are 160.21M, and float is at 156.67M with Short Float at 10.37%. Institutions hold 102.53% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 22.88 million shares valued at $149.16 million. The investor’s holdings represent 14.3868 of the IRWD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 21.56 million shares valued at $140.59 million to account for 13.6737 of the shares outstanding. The other top investors are SARISSA CAPITAL MANAGEMENT LP which holds 16.39 million shares representing 10.3073 and valued at over $106.86 million, while UBS GROUP AG holds 7.1023 of the shares totaling 11.2 million with a market value of $73.03 million.
Ironwood Pharmaceuticals Inc (IRWD) Insider Activity
The most recent transaction is an insider sale by MCCOURT Thomas A, the company’s Chief Executive Officer. SEC filings show that MCCOURT Thomas A sold 139,064 shares of the company’s common stock on Feb 10 ’25 at a price of $1.76 per share for a total of $0.24 million. Following the sale, the insider now owns 1.16 million shares.
Ironwood Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 10 ’25 that Silver Ronald (Principal Accounting Officer) sold a total of 12,048 shares of the company’s common stock. The trade occurred on Feb 10 ’25 and was made at $1.76 per share for $21204.0. Following the transaction, the insider now directly holds 0.28 million shares of the IRWD stock.
Still, SEC filings show that on Feb 10 ’25, Shetzline Michael (SVP, CMO, Head-Res&Drug) disposed off 41,269 shares at an average price of $1.76 for $72633.0. The insider now directly holds 554,007 shares of Ironwood Pharmaceuticals Inc (IRWD).
